• Chunfeng Hou, Chunfeng Ren, Luan Luan, and Shujie Li.
• Department of Rheumatology, Jining No.1 People's Hospital, Jining, China.
• Medicine (Baltimore). 2023 Oct 13; 102 (41): e35655e35655.

RationaleA chronic autoimmune liver disease known as primary biliary cholangitis (PBC) that selectively destructs small intrahepatic biliary epithelial cells and may result in biliary cirrhosis and eventually liver transplantation or death. PBC is associated with various other extrahepatic autoimmune diseases; however, the combination of PBC with ankylosing spondylitis has been rarely reported in the literature. Here, we reported a case of PBC with ankylosing spondylitis to improve our understanding of such coexistence and provide new ideas for the treatment of such patients.Patient ConcernsA 54-year-old man was presented to the Department of Rheumatology because of an abnormal liver function test for 7 years, chest and back pain for 1 year, and low back pain for 2 months.DiagnosesPrimary biliary cholangitis, ankylosing spondylitis, and old pulmonary tuberculosis.InterventionsThe patient refused to use nonsteroidal anti-inflammatory drugs, conventional synthetic disease-modifying antirheumatic drugs, and biologic disease-modifying antirheumatic drugs; thus, he was treated with methylenediphosphonate (99Tc-MDP) and ursodeoxycholic acid (UDCA).OutcomesThe patient achieved remission with UDCA and 99Tc-MDP therapy.LessonsIn the treatment of PBC combined with other disorders, the characteristics of different diseases should be considered. The patient reported herein was treated with 99Tc-MDP and UDCA, and his condition improved; thus, we consider 99Tc-MDP to be an effective treatment. Furthermore, in line with the current understanding of the pathogenesis of PBC and ankylosing spondylitis, we hypothesize that interleukin-17 inhibitor is an effective treatment for such patients.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…